![]() |
|
|
Vol. 281, Issue 1, 330-336, 1997
Division of Clinical Pharmacology (Y.C., A.J.J.W.) and
Pulmonary
Department (J.S.), Vanderbilt University School of Medicine, Nashville,
Tennessee
Our objective was to examine the effect of rifampin on codeine's
pharmacodynamics and pharmacokinetics in extensive (EMs) and poor (PMs)
metabolizers of debrisoquin. Fifteen healthy, nonsmoking males, 9 EMs
and 6 PMs of debrisoquin, received codeine (120 mg) before and after
rifampin (600 mg/d) for 3 weeks. The effects of codeine on respiration,
pupil diameter and psychomotor performance were measured before codeine
administration and during each study day. The pharmacokinetics of
codeine were determined from the respective plasma and urine
concentrations. Before the administration of rifampin, the
pharmacodynamic effects of codeine were more prominent in the EMs
(P < .01). Rifampin significantly enhanced codeine oral clearance
by increasing its metabolic clearances through N-demethylation and
glucuronidation in both phenotypes, but its O-demethylation was induced
only in EMs. Relative to base-line values, codeine N-demethylation was
induced to a greater extent, resulting in a marked reduction in the
plasma concentrations of codeine and codeine metabolites and elevated
plasma concentrations of norcodeine, norcodeine-glucuronide, and
normorphine. The reduction in morphine plasma concentration was
associated in the EMs with a significant attenuation of codeine's
respiratory and psychomotor effects, whereas its miotic effect was
unaltered. In PMs, codeine's respiratory and psychomotor effects were
unaltered by rifampin, but its pupillary effect was reduced. Codeine
O-demethylation to produce morphine can be significantly induced by
rifampin, but this induction is phenotypically determined. However,
because (relative to base-line values) rifampin enhanced codeine
N-demethylation more than codeine O-demethylation, morphine plasma
concentrations were reduced
and hence codeine's pharmacodynamic
effects were attenuated
in EMs of debrisoquin.
This article has been cited by other articles:
![]() |
M. A. Boyd, X. Zhang, A. Dorr, K. Ruxrungtham, S. Kolis, K. Nieforth, T. Kinchelow, N. Buss, and I. H. Patel Lack of Enzyme-Inducing Effect of Rifampicin on the Pharmacokinetics of Enfuvirtide J. Clin. Pharmacol., December 1, 2003; 43(12): 1382 - 1391. [Abstract] [Full Text] [PDF] |
||||
![]() |
American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis Am. J. Respir. Crit. Care Med., February 15, 2003; 167(4): 603 - 662. [Full Text] [PDF] |
||||
![]() |
C. B. Berde and N. F. Sethna Analgesics for the Treatment of Pain in Children N. Engl. J. Med., October 3, 2002; 347(14): 1094 - 1103. [Full Text] [PDF] |
||||
![]() |
C. K. Finch, C. R. Chrisman, A. M. Baciewicz, and T. H. Self Rifampin and Rifabutin Drug Interactions: An Update Arch Intern Med, May 13, 2002; 162(9): 985 - 992. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. G. Williams, D. J. Hatch, and R. F. Howard Codeine phosphate in paediatric medicine Br. J. Anaesth., March 1, 2001; 86(3): 413 - 421. [Abstract] [Full Text] [PDF] |
||||